By Dr. Joshua Sturgeon

Next Lesson - Acute Kidney Injury

 Urinary System 


Contents

Abstract

  • In adults, diabetic nephropathy (kidney damage caused by diabetes) is one of the most common secondary causes of nephrotic syndrome. Nephrotic syndrome means heavy protein loss in the urine, with a low blood albumin and oedema. A secondary cause is a disease outside the kidney, here diabetes.
  • Diabetic nephropathy is a serious condition that develops in roughly 20-40% of people with diabetes. Only a minority of those affected progress to kidney failure, and modern treatment slows progression.
  • Pathological changes to the glomerulus are classically taught as a step-wise progression, matched by a step-wise progression of signs and symptoms, although not every patient follows the same sequence.
  • Management is based upon primary prevention (stopping the disease before it starts). If primary prevention fails, blocking the renin-angiotensin-aldosterone system (RAAS, a hormone system that raises blood pressure) is an important part of delaying progression of the disease. In type 2 diabetes with chronic kidney disease, NICE also recommends an SGLT-2 inhibitor (sodium-glucose co-transporter 2 inhibitor, a tablet that makes the kidneys pass more glucose into the urine).

Core

Overview

Diabetic nephropathy is one of the commonest secondary causes of nephrotic syndrome in adults (a secondary cause is a disease outside the kidney, here diabetes). It is a glomerulopathy (a disease of the glomerulus, the kidney's filtering unit) and NOT a glomerulonephritis (glomerulonephritis means inflammation of the glomerulus, which is not present here). It is the commonest cause of end-stage renal disease (ESRD), but only a minority of people with diabetes ever reach it. Higher figures have been quoted: about 30% of people with type 1 diabetes and 10 to 40% of those with type 2 diabetes eventually developing ESRD (National Kidney Foundation). Registry data suggest lower figures: in Finland, 7.8% of people diagnosed with type 1 diabetes before the age of 30 had developed ESRD 30 years after diagnosis.

 

 

Pathological Changes

The following changes describe the classic teaching model of diabetic nephropathy, listed roughly in the order in which they classically appear. Functional and structural changes can overlap, and individuals do not all progress through a fixed sequence:

  1. Hyperfiltration (a raised filtration rate) and capillary hypertension (raised pressure in the glomerular capillaries): early haemodynamic changes (changes in blood flow and pressure). They can occur before overt proteinuria (protein in the urine) or any fall in kidney function, but they do not always come before the structural changes listed below.
  2. Glomerular basement membrane (GBM) thickening: the GBM is the middle layer of the glomerular filter, between the capillary lining and the podocytes (the cells that wrap around the capillaries, described below)
  3. Mesangial expansion: the mesangium is the central stalk of the glomerulus that supports the capillary loops. It is made of mesangial cells (smooth muscle-like cells) and their matrix.
  4. Podocyte injury: podocytes are the cells that wrap around the glomerular capillaries and form the outer layer of the filter
  5. Glomerular sclerosis (scarring of the glomeruli) and arteriosclerosis (thickening and hardening of the arteriole walls)

In diabetes, the high blood glucose means more glucose is filtered at the glomerulus. In the proximal tubule (the first part of the tube that carries filtered fluid away from the glomerulus), glucose is reabsorbed together with sodium by sodium-glucose co-transporters (mainly SGLT-2). The extra filtered glucose therefore drives increased reabsorption of glucose and sodium chloride (NaCl) in the proximal tubule.

This means less NaCl is left in the fluid that reaches the macula densa (sensor cells in the wall of the distal tubule). The decreased delivery of NaCl distally reduces tubuloglomerular feedback, the signal that normally constricts the afferent arteriole. The result is afferent arteriolar vasodilation (the afferent arteriole carries blood into the glomerulus). This vasodilation is compounded by hyperglycaemia (high blood glucose) and high blood amino acid levels. The efferent arteriole (which carries blood out of the glomerulus) vasoconstricts due to a high local level of angiotensin II (a hormone that constricts blood vessels). The vasodilation of the afferent arteriole and vasoconstriction of the efferent arteriole lead to high glomerular capillary pressure and thus the Glomerular Filtration Rate (GFR) is initially increased.

The high intraglomerular pressure (the pressure inside the glomerulus) leads to mesangial expansion and GBM thickening. The filter also develops some enlarged pores, which let larger proteins leak into the urine. Podocytes are damaged as well, and injured podocytes are thought to disturb the normal upkeep of the GBM. Over time, these changes cause glomerulosclerosis (scarring of the glomeruli) and hyaline deposition (a build-up of glassy protein material) in arterioles, resulting in arteriosclerosis.

 

 

Clinical Signs and Symptoms

Clinical findings in diabetic nephropathy are often described using a classic sequence. In practice, albuminuria (albumin in the urine) and kidney function change in different ways in different people. The findings do not match fixed stages of structural damage in every patient.

Hyperfiltration may cause an early increase in GFR. A raised GFR is a change in function, so it does not show that the renal histology (the kidney tissue seen under a microscope) is normal. GBM thickening and mesangial expansion can develop during a clinically silent period before albuminuria becomes evident.

Moderately increased albuminuria, traditionally called microalbuminuria, is an early clinical marker in the classic course of diabetic nephropathy. It means a urine albumin:creatinine ratio (ACR) of 3 to 30 mg/mmol (mg of albumin per mmol of creatinine). This amount of albumin is too small for a standard urine dipstick (a test strip dipped in urine) to detect. It is therefore found with the ACR test, which NICE advises doing regularly in people with diabetes. Structural lesions (areas of damaged tissue) may already be present when microalbuminuria is detected. In the classic course, the sustained fall in GFR comes later, but GFR should still be measured rather than assumed to be normal. Albuminuria may regress or progress, and a reduction in albumin excretion does not by itself demonstrate reversal of structural kidney damage. Follow both albuminuria and kidney function over time.

The next sign is overt proteinuria (severely increased albuminuria, an ACR over 30 mg/mmol). This can be detected on a simple urinalysis dipstick (a chemical test strip dipped into a urine sample), although NICE advises using the ACR to detect and monitor it. At this stage, the GFR falls in a linear pattern. Before modern treatment, this stage was thought to lead to a decline to ESRD in about 7 years in many people. Older reports gave a wide range, from 5 to 20 years, and some people died of cardiovascular disease without reaching ESRD. The damage is usually not reversible, but treatment can slow its progression. This stage is associated with worsening systemic hypertension and microvascular changes (changes in the small blood vessels, such as arteriosclerosis). The microvascular changes cause tissue ischaemia.

 

 

Risk Factors and Primary Prevention

Not everyone with diabetes will develop diabetic nephropathy, but certain risk factors can increase the chances. Some of them, such as blood pressure, blood glucose and smoking, can be changed:

  • Genetic susceptibility: in people with type 1 diabetes, having a first-degree relative (a parent, brother, sister or child) with diabetic nephropathy increases the risk. It raises the chance of nephropathy but does not make it certain.
  • Hypertension
  • Hyperglycaemia
  • High level of hyperfiltration (a raised GFR early in diabetes)
  • Increasing age
  • Duration of diabetes
  • Smoking
  • Ethnicity: Black and South Asian people are more likely to develop kidney disease with diabetes

Primary prevention means intervening before the negative health effects occur, by controlling modifiable (changeable) risk factors. Primary prevention of diabetic nephropathy is based on tight blood glucose and blood pressure control. In type 2 diabetes, NICE now advises offering most adults an SGLT-2 inhibitor (sodium-glucose co-transporter 2 inhibitor) alongside metformin (a first-line diabetes tablet), partly for its kidney-protective benefits. There is also some evidence that stopping smoking and statin therapy (cholesterol-lowering drugs) can help.

In type 1 diabetes, tight glycaemic control with multiple daily insulin injections or an insulin pump can bring blood glucose close to normal. This must be done without causing problematic hypoglycaemia (low blood glucose). Near-normal blood glucose can reverse the initial hyperfiltration and delay microalbuminuria. If microalbuminuria has developed, tight glycaemic control can reduce it. Once overt proteinuria has developed, glucose control remains part of a combined treatment approach. The damage is usually not reversible, and treatment aims to slow the fall in GFR (see Management).

 

 

Management

If primary prevention fails and diabetic nephropathy develops, management is aimed at controlling microalbuminuria and proteinuria, to slow the loss of kidney function and reduce cardiovascular risk.

This is achieved by inhibiting the Renin-Angiotensin-Aldosterone System (RAAS) with ACE inhibitors (angiotensin-converting enzyme inhibitors) or angiotensin receptor blockers (ARBs, which block the action of angiotensin II). NICE advises offering one of these to adults with diabetes and chronic kidney disease (CKD) whose urine ACR is 3 mg/mmol or more. CKD means long-term kidney damage or loss of kidney function. The dose should be the highest licensed dose the person can tolerate. An ACE inhibitor and an ARB should not be given together. RAAS inhibition reduces glomerular hyperfiltration primarily through vasodilation of the efferent arteriole, which lowers the pressure inside the glomerulus. The lower pressure reduces proteinuria and slows the progression of diabetic nephropathy. RAAS inhibition can increase the risk of hyperkalaemia (high blood potassium) and an initial fall in eGFR (estimated GFR, calculated from a blood creatinine test). NICE therefore advises measuring serum potassium and eGFR before starting, and again 1 to 2 weeks after starting and after each dose increase.

NICE also recommends an SGLT-2 inhibitor alongside the ACE inhibitor or ARB, for its kidney-protective effect. This applies to adults with type 2 diabetes and CKD whose eGFR is 20 to 90 ml/min/1.73 m². Finerenone (a drug that blocks the aldosterone receptor) can be added for some adults with type 2 diabetes, albuminuria and CKD stage 3 or 4. CKD is staged from 1 to 5, with 5 the most severe. NICE advises finerenone only as an add-on, and only for people who meet two conditions. First, they are already taking the highest tolerated dose of an ACE inhibitor or ARB and of an SGLT-2 inhibitor (unless a drug is unsuitable for them). Second, their eGFR is 25 ml/min/1.73 m² or more.

The inhibition of RAAS is just one part of a multi-faceted therapeutic approach. The approach also includes blood pressure control, statin therapy (to reduce cardiovascular risk) and blood glucose control to an individually agreed target (avoiding hypoglycaemia). Diet and lifestyle matter too: moderate protein intake (NICE advises against low-protein diets in CKD) and cardiovascular risk management (exercise, diet modifications, and stopping smoking). For adults with CKD, NICE advises a clinic blood pressure below 140/90 mmHg, or below 130/80 mmHg if the urine ACR is 70 mg/mmol or more.

 

Edited by: Dr. Maddie Swannack

Reviewed by: Dr. Thomas Burnell and Dr. Marcus Judge

Quiz

Preview the Diabetic Nephropathy quiz